Johnson & Johnson's TREMFYA achieves primary endpoint in Phase 3b APEX study
Prostatype Genomics expects minimal impact from proposed US tariffs
Tasman Therapeutics to raise USD175m in Series A funding
ERBC collaborates with Menarini Biotech to accelerate biopharmaceuticals development
Sanofi's rilzabrutinib receives US orphan drug designation for two rare diseases
Circio Holding and Entos Pharmaceuticals collaborate on circular RNA delivery
Hoth Therapeutics partners with Washington University to advance Alzheimer's disease research
Mabwell's B7-H3-targeting ADC clinical trial application receives Chinese regulatory approval
Amygdala Neurosciences selects ANS-858 as lead clinical candidate for substance use disorder
4basebio announces award of GMP certification for UK DNA manufacturing facility
Ananda Pharma's MRX1 receives ethics approval for Phase 1 study in Australia
GRIN Therapeutics' radiprodil granted Priority Medicine designation in Europe
AKAGERA Medicines completes first cohort in phase 1 SAD/MAD study of AKG-100
Yingli Pharma's linperlisib Phase 3 registration study approved by US FDA
Oncopeptides secures FDA approval to resume OPD5 clinical development